The recent collaboration between Merck and InnoCore Pharmaceuticals for the development of a new drug delivery platform that will improve compliance could be a step forward in the delivery of biologics, according to Rahael Maladwala, pharma analyst at GlobalData.
step forward
“One of the biggest environmental unmet needs in the pharmaceutical market is a lack of compliance,” said Maladwala. “Whether this is due to invasive drug delivery, adverse events, or a complicated dosing regime, many patients that start a biologic treatment do not finish the course.”